Biotechs dive deeper into targeted cancer research, despite costs
CHICAGO — An AstraZeneca cancer drug works best in people with an uncommon mutation. For a recent study evaluating whether…
Read more
Experimental drug delays Type 1 diabetes in research first
An experimental biologic drug appeared to substantially delay the development of Type 1 diabetes in people at high risk for…
ADA: J&J’s struggling Invokana slashes heart, kidney risks in latest trial win
SAN FRANCISCO—Johnson & Johnson and its fellow SGLT2 drug makers are all working to show benefits for patients with kidney…
Roche touts phase 2 Gazyva data in lupus patients with a potentially fatal kidney complication
One brand-new FDA approval and one trial win for its blood cancer drug Gazyva added up to a double dose…
NASH trial miss halves CymaBay’s market value
An experimental drug from CymaBay Therapeutics missed the primary endpoint of a mid-stage NASH trial, cutting the stock price of the California…
Phoenix Molecular Designs and WuXi STA Reach Drug Supply Milestone to Support Phase I/Ib Study of PMD-026 for TNBC
VANCOUVER, British Columbia and SAN DIEGO, June 4, 2019 – Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics targeting essential…
PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility
PCI secures third site for Clinical Trials storage, central logistics and distribution center Philadelphia, PA – June 4, 2019 PCI Pharma…
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial…
MacroGenics dives as breast cancer drug shows small improvement
Shares of Maryland-based MacroGenics fell by nearly 20% Tuesday after its experimental drug for advanced breast cancer showed only a…
FDA ‘open for business’ in considering real-world evidence, Sharpless says
PHILADELPHIA — The Food and Drug Administration is “open for business” in considering real-world evidence to clear expanded uses of…